Founded in 1984 and headquartered in suburban Atlanta, Georgia, CryoLife is dedicated to improving health and quality of life through the transplantation of human tissues, biomaterials and medical devices. CryoLife is a leader in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries throughout the United States and Canada. CryoLife markets BioGlue Surgical Adhesive, an innovative biosurgical device that is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels. BioGlue is also CE Marked in the European Community and approved in Canada and Australia for use in soft tissue repair. BioGlue is distributed in more than 50 countries, with worldwide sales of $40.0 million in 2006. CryoLife also distributes the CryoLife-O'Brien Stentless porcine heart valve, which is CE marked for distribution within the European Community. CryoLife continues to invest in research and development to provide innovative, new products that will benefit patients around the world. The Companys Rand;D efforts are focused on Protein Hydrogel Technologies (BioDisc for spinal repair and BioFoam for abdominal aortic aneurysms and severe wounds) and ProPatch Soft Tissue Repair Matrix (for rotator cuff repair).
This article uses content from
http://www.AboutUs.org
